TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05616013

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bimagrumab
Description: Human monoclonal antibody to the activin receptor type II

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bimagrumab
Description: Human monoclonal antibody to the activin receptor type II

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bimagrumab
Description: Human monoclonal antibody to the activin receptor type II
Study: NCT04947280

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotatic Radiation Therapy
Description: Participants prescribed to receive 9 Gy x 3 or 10 Gy x3 image-guided fractionated stereotatic radiation therapy.
Study: NCT05616013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bimagrumab
Description: Human monoclonal antibody to the activin receptor type II

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bimagrumab
Description: Human monoclonal antibody to the activin receptor type II

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bimagrumab
Description: Human monoclonal antibody to the activin receptor type II

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bimagrumab
Description: Human monoclonal antibody to the activin receptor type II

Intervention type: DRUG
Group type: OTHER
Intervention: Semaglutide
Description: Glucagon-like peptide-1 (GLP-1) receptor agonist

Intervention type: DRUG
Group type: OTHER
Intervention: Semaglutide
Description: Glucagon-like peptide-1 (GLP-1) receptor agonist

Intervention type: DRUG
Group type: OTHER
Intervention: Semaglutide
Description: Glucagon-like peptide-1 (GLP-1) receptor agonist

Intervention type: DRUG
Group type: OTHER
Intervention: Semaglutide
Description: Glucagon-like peptide-1 (GLP-1) receptor agonist

Intervention type: DRUG
Group type: OTHER
Intervention: Semaglutide
Description: Glucagon-like peptide-1 (GLP-1) receptor agonist

Intervention type: DRUG
Group type: OTHER
Intervention: Semaglutide
Description: Glucagon-like peptide-1 (GLP-1) receptor agonist

Intervention type: OTHER
Group type: OTHER
Intervention: Bimagrumab Placebo
Description: Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Bimagrumab Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bimagrumab Placebo
Description: Placebo
Study: NCT05364021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP352
Description: LP352 administered three times daily, orally or through G-tube

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for LP352 administered three times daily, orally or through G-tube
Study: NCT04538482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH Diet
Description: Participant will receive foods following the DASH dietary pattern for 28 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard American diet
Description: Participants will receive foods following the standard American diet for 28 days.
Study: NCT05961709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given by IV (vein)
Study: NCT06016062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC148 Monotherapy
Description: RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC148+docetaxel Combination Therapy
Description: RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle； Docetaxel will be administered as an IV infusion on Day 1 of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC148+RC48 Combination Therapy
Description: RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle； RC48 will be administered as an IV infusion on Day 1 of each 2-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC148+RC48 Combination Therapy
Description: RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle； RC48 will be administered as an IV infusion on Day 1 of each 2-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC148+RC88 Combination Therapy
Description: RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle； RC88 will be administered as an IV infusion on Day 1 of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC148+RC88 Combination Therapy
Description: RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle； RC88 will be administered as an IV infusion on Day 1 of each 3-week cycle.
Study: NCT05240937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based self-compassion will be applied
Description: A mindfulness-based self-compassion program will be applied to this group of patients who have had breast cancer and have fully completed their treatment.
Study: NCT06010667

Intervention type: DRUG
Intervention: Envafolimab
Description: With or without Envafolimab
Study: NCT05355012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5A organizational innovation
Description: This project is based on three strategic axes:~* A gradation of the care offer allowing to adapt the means and resources mobilized on the territory~* Personalized care by developing specific treatment paths based on the risk factors and/or vulnerabilities of the pregnant woman~* Coordination of territorial resources to support pregnant women in quitting smoking These three key elements will make it possible to propose a partnership-based, multi-professional, coordinated and integrated approach to the territory, supported by the technical resources and expertise available in the territory. It invites a majority of non-specialized actors to invest in the process of supporting pregnant women in quitting smoking, multiplying and potentiating their actions with this population.
Study: NCT04574024

Intervention type: DRUG
Group type: OTHER
Intervention: NBT-NM108
Description: MS Patients received NBT-NM108 at 60 g/day.
Study: NCT05377086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth 3-Dimensional scoliosis exercise
Description: Schroth 3-Dimensional scoliosis exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional scoliosis exercise
Description: conventional scoliosis exercise
Study: NCT05838170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lotilaner Gel, 2.0%
Description: Lotilaner Gel, 2.0% (TP-04) is an aqueous gel formulation of lotilaner, a member of the isoxazoline family of compounds and parasiticide that selectively inhibits parasite-specific gamma-aminobutyric acid (GABA)-gated chloride channels (GABA-Cls).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control gel
Description: Aqueous gel
Study: NCT06328894

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
Study: NCT06016062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC148+RC88 Combination Therapy
Description: RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle； RC88 will be administered as an IV infusion on Day 1 of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC148/Bevacizumab+RC88 Combination Therapy
Description: RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle; RC88 will be administered as an IV infusion on Day 1 of each 3-week cycle; Bevacizumab will be administered as an IV infusion on Day 1 of each 3-week cycle
Study: NCT05037929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astegolimab
Description: Participants will receive SC astegolimab Q2W or Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astegolimab
Description: Participants will receive SC astegolimab Q2W or Q4W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive SC placebo Q2W.
Study: NCT06086951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pai.ACT Group
Description: The Pai.ACT mobile app is an innovative therapeutic tool that utilizes Acceptance and Commitment Therapy (ACT). It integrates a sophisticated algorithm to analyze self-reported data and conversation texts when the user interacts with the AI chatbot and identifies what psychological inflexibility processes are required to be the most essential to be addressed for process-matched ACT interventions. These interventions, including self-help modules and experiential exercises, are enhanced with dynamic animations and audio metaphors. The app also offers 4-6 video-based individual ACT sessions with a dedicated counseling team and a referral system for intensive psychological support, all underpinned by empirical evidence from a previous ACT trial in Hong Kong.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Both the Pai.ACT group and the control group will receive conventional familial support offered by the hospital's Children with Complexity Community Support Programme (CCCSP) and allied Non-Governmental Organizations (NGOs). This support encompasses disseminating educational content focused on the management of children's affective and behavioral manifestations.
Study: NCT06647342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: In the standard arm, Bleomycin (Baxter, Germany) at a dose of 15.000 IU/m² is used. In the dose reduction arm, a dose of 7500 IU/m² is used. Note that in Denmark bleomycin is dosed by international units, whereas other countries may use respectively U (units) or mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: In the standard arm, Bleomycin (Baxter, Germany) at a dose of 15.000 IU/m² is used. In the dose reduction arm, a dose of 7500 IU/m² is used. Note that in Denmark bleomycin is dosed by international units, whereas other countries may use respectively U (units) or mg.
Study: NCT04829240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Veterans Anxiety Skills Training Intervention
Description: Modular anxiety intervention designed for Primary Care-Mental Health Integration settings, including up to six 30-minute sessions occurring approximately every 2 weeks, in which Veterans select modules of interest to them to complete, with an emphasis on psychoeducation and cognitive-behavioral coping strategies for self management of anxiety symptoms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PCMHI Usual Care
Description: Appointment with Primary Care-Mental Health Integration provider at local primary care clinic for anxiety treatment; provider delivers whatever interventions they deem appropriate and collaboratively decides with patients whether and when to meet again as in routine PCMHI care
Study: NCT06328894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study: NCT06539663

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: OmniLenz®
Description: OmniLenz® applied for 1 week in all patients after development of corneal perforation
Study: NCT05448937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lesion sterilization and tissue repair
Description: Pulp therapy for necrotic primary molars

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: zinc oxide and eugenol pulpectomy
Description: Pulp therapy for necrotic primary molars
Study: NCT06092541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention Group: pericervical anesthesia
Description: Patients assigned to the Intervention Group will receive Pericervical anesthesia before performing Hysteroscopy.~Specifically, for the administration of pericervical analgesia, Mepivacaine/Lidocaine 1.5% 10/15 ml (max dose 7 mg/kg) will be used and pericervical infiltration will be performed at 0.5 cm depth at 3 and 9 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nitroux Oxide anesthesia
Description: Patients assigned to the Control Group will receive Nitrous Oxide anesthesia before hysteroscopy
Study: NCT04764188

Intervention type: DRUG
Intervention: Alectinib
Description: Participants will receive alectinib in accordance with local clinical practice and local labeling.

Intervention type: DRUG
Intervention: Alectinib
Description: Participants will receive alectinib in accordance with local clinical practice and local labeling.
Study: NCT06477016

Intervention type: DEVICE
Intervention: OsciPulse
Description: Non-invasive device that provides rapid pulses of compression of the calves to modify venous blood flow patterns in immobilized persons.

Intervention type: DEVICE
Intervention: Intermittent Pneumatic Compression
Description: Non-invasive device that provides rapid pulses of compression of the calves to modify venous blood flow patterns in immobilized persons.
Study: NCT06031688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT05279742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MANP
Description: Single subcutaneous injection 5 µg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MANP
Description: Single subcutaneous injection 5 µg/Kg
Study: NCT06031688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy
Description: Undergo lymphoscintigraphy scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphoscintigraphy
Description: Undergo lymphoscintigraphy scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT06275048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrist/hand immobilization
Description: Study participants will have their left wrist/hand immobilized with a splint for 7 days. The splint will be worn 24 hours per day.
Study: NCT05279742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Description: Oral single dose 97/103 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Description: Oral single dose 97/103 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Oral single dose that contains no active ingredient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Oral single dose that contains no active ingredient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Oral single dose that contains no active ingredient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Oral single dose that contains no active ingredient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection Placebo
Description: Single subcutaneous injection that contains no active ingredient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injection Placebo
Description: Single subcutaneous injection that contains no active ingredient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection Placebo
Description: Single subcutaneous injection that contains no active ingredient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injection Placebo
Description: Single subcutaneous injection that contains no active ingredient
Study: NCT05870436

Intervention type: DIAGNOSTIC_TEST
Intervention: Methacholine Choline Provocation Test
Description: Perform methacholine choline provocation test according to the protocol

Intervention type: DIAGNOSTIC_TEST
Intervention: Methacholine Choline Provocation Test
Description: Perform methacholine choline provocation test according to the protocol
Study: NCT04849832

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SIC
Description: Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SIC + tea
Description: Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich with 2g of tea brewed for 5 minutes

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeSO4
Description: Ferrous sulfate solution serves as a positive control - and whose absorption is well known.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeSO4 + tea
Description: Ferrous sulfate solution given with 2g of tea brewed for 5 minutes - expected iron absorption inhibition
Study: NCT05399342

Intervention type: OTHER
Intervention: No Intervention
Description: Patients in the LAAOS III trial either had or did not have their left atrial appendage occluded at the time of surgery in that trial. No further intervention is required in this cohort, it is observational follow-up only.
Study: NCT06552780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENs , ultrasound therapy
Description: effect of high intensity laser versus ischemic compression on myofascial trigger points in the upper trapezius
Study: NCT06211790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib, Everolimus and Tislelizumab
Description: Anlotinib (PO, QD), Everolimus (PO, QD) and Tislelizumab (IV, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib, Everolimus and Tislelizumab
Description: Anlotinib (PO, QD), Everolimus (PO, QD) and Tislelizumab (IV, Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib, Everolimus and Tislelizumab
Description: Anlotinib (PO, QD), Everolimus (PO, QD) and Tislelizumab (IV, Q3W)
Study: NCT04837885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection
Description: Intra-hepatic injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
Study: NCT05756907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SON-1010
Description: SON-1010 +/- Atezolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SON-1010
Description: SON-1010 +/- Atezolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SON-1010
Description: SON-1010 +/- Atezolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SON-1010
Description: SON-1010 +/- Atezolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SON-1010
Description: SON-1010 +/- Atezolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SON-1010
Description: SON-1010 +/- Atezolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SON-1010
Description: SON-1010 +/- Atezolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SON-1010
Description: SON-1010 +/- Atezolizumab
Study: NCT06552780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENs , ultrasound therapy
Description: effect of high intensity laser versus ischemic compression on myofascial trigger points in the upper trapezius

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENs , ultrasound therapy
Description: effect of high intensity laser versus ischemic compression on myofascial trigger points in the upper trapezius
Study: NCT06560125

Intervention type: OTHER
Intervention: Standard care
Description: Treatment appropriate for wound condition

Intervention type: OTHER
Intervention: Standard care
Description: Treatment appropriate for wound condition
Study: NCT05347719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT Intervention
Description: Eight weekly two-hour mindful MBCT intervention sessions involving training in mindfulness meditation and cognitive-behavioral methods. Sessions will be designed to increase participant awareness of internal reactions that trigger relapse in MDD and to provide participants with techniques to detach from dysfunctional cognitive processes and redirect their attention to experiences. Outside of the sessions, participants will be assigned daily homework exercises and provided with handouts and audio recordings of mindfulness exercises to use in their practice.